Cantor Fitzgerald reissued their overweight rating on shares of Glaukos Corp (NYSE:GKOS) in a research report report published on Thursday, May 4th. Cantor Fitzgerald currently has a $54.00 price target on the medical instruments supplier’s stock.
Several other research analysts have also weighed in on the company. Zacks Investment Research lowered Glaukos Corp from a hold rating to a sell rating in a report on Tuesday, May 2nd. BMO Capital Markets reissued a buy rating and issued a $54.00 price target on shares of Glaukos Corp in a research note on Tuesday, April 11th. TheStreet raised Glaukos Corp from a d+ rating to a c rating in a research report on Wednesday, March 1st. Finally, Stifel Nicolaus boosted their price target on Glaukos Corp from $45.00 to $55.00 and gave the stock a positive rating in a research report on Tuesday, February 28th. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. Glaukos Corp presently has a consensus rating of Buy and an average target price of $48.17.
Glaukos Corp (NYSE:GKOS) traded up 0.067% during midday trading on Thursday, reaching $37.315. The company’s stock had a trading volume of 272,809 shares. The company has a market capitalization of $1.28 billion, a price-to-earnings ratio of 339.227 and a beta of 1.37. The company’s 50-day moving average price is $45.54 and its 200-day moving average price is $40.79. Glaukos Corp has a 1-year low of $23.47 and a 1-year high of $52.49.
Glaukos Corp (NYSE:GKOS) last posted its earnings results on Wednesday, March 1st. The medical instruments supplier reported $0.00 earnings per share for the quarter. The firm had revenue of $33.17 million for the quarter, compared to analyst estimates of $29.49 million. Glaukos Corp had a return on equity of 2.05% and a net margin of 2.07%. The company’s revenue for the quarter was up 63.6% on a year-over-year basis. During the same period in the previous year, the company posted ($0.07) earnings per share. On average, analysts predict that Glaukos Corp will post $0.21 earnings per share for the current fiscal year.
In other Glaukos Corp news, Director Orbimed Advisors Llc sold 382,538 shares of the company’s stock in a transaction on Tuesday, March 14th. The shares were sold at an average price of $45.33, for a total transaction of $17,340,447.54. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 36.80% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in GKOS. State Board of Administration of Florida Retirement System boosted its position in Glaukos Corp by 1.9% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 7,699 shares of the medical instruments supplier’s stock worth $264,000 after buying an additional 140 shares during the period. Inspirion Wealth Advisors LLC boosted its position in Glaukos Corp by 7.4% in the first quarter. Inspirion Wealth Advisors LLC now owns 9,400 shares of the medical instruments supplier’s stock worth $482,000 after buying an additional 650 shares during the period. American International Group Inc. boosted its position in shares of Glaukos Corp by 7.1% in the first quarter. American International Group Inc. now owns 10,293 shares of the medical instruments supplier’s stock valued at $528,000 after buying an additional 681 shares during the last quarter. First Republic Investment Management Inc. boosted its position in shares of Glaukos Corp by 9.1% in the fourth quarter. First Republic Investment Management Inc. now owns 12,613 shares of the medical instruments supplier’s stock valued at $432,000 after buying an additional 1,047 shares during the last quarter. Finally, Teachers Advisors LLC boosted its position in shares of Glaukos Corp by 5.7% in the fourth quarter. Teachers Advisors LLC now owns 27,789 shares of the medical instruments supplier’s stock valued at $953,000 after buying an additional 1,506 shares during the last quarter. 77.95% of the stock is currently owned by institutional investors.
About Glaukos Corp
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.
Receive News & Ratings for Glaukos Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corp and related companies with MarketBeat.com's FREE daily email newsletter.